Alogliptin and Metformin Hydrochloride Sustained-release Tablets(Taizhou Overseas Pharma)

阿格列汀盐酸二甲双胍缓释片（越洋医药）

Report date: 2025/08/26 16:16:42

Base Information

Drug NameAlogliptin and Metformin Hydrochloride Sustained-release Tablets(Taizhou Overseas Pharma)
Drug Alias Name阿格列汀盐酸二甲双胍缓释片（2.2类改良型）
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Overseas Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG